{"id":1355,"date":"2018-01-24T09:03:28","date_gmt":"2018-01-24T08:03:28","guid":{"rendered":"http:\/\/www.nanexa.com\/?p=1355"},"modified":"2018-01-24T09:03:28","modified_gmt":"2018-01-24T08:03:28","slug":"nanexa-forstarker-med-advisory-board-inom-onkologi","status":"publish","type":"post","link":"https:\/\/nanexa.com\/sv\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","title":{"rendered":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi"},"content":{"rendered":"<p>Uppsala 2018-01-23<strong>\u00a0<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi<\/strong><\/p>\n<p>Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det. I syfte att staka ut v\u00e4gen f\u00f6r Nanexas egna produktprojekt har Bolaget samlat ett Advisory Board med djupa kunskaper inom onkologiomr\u00e5det.<\/p>\n<p>Gruppen, som best\u00e5r av fyra externa medlemmar och ett antal medlemmar fr\u00e5n Nanexa, kommer identifiera relevanta indikationer och aktiva substanser som matchar viktiga medicinska behov inom onkologiomr\u00e5det d\u00e4r Nanexas drug delivery-plattform PharmaShell<sup>\u00ae<\/sup> erbjuder nya behandlingsf\u00f6rdelar. Rekommendationer fr\u00e5n denna grupp kommer tillsammans med marknadsdata f\u00f6r relevanta indikationer leda till beslut om produktprojekt baserat p\u00e5 PharmaShell<sup>\u00ae<\/sup>.<\/p>\n<p>De externa medlemmarna i Nanexas Advisory Board \u00e4r:<\/p>\n<p><em>Jan-Olof Fernberg<\/em>, Docent i klinisk onkologi<\/p>\n<p><em>Matthias L\u00f6hr<\/em>, Professor och \u00f6verl\u00e4kare, Enheten f\u00f6r kirurgi, Karolinska Universitetssjukhuset<\/p>\n<p><em>Bengt Westermark<\/em>, Professor,\u00a0Institutionen f\u00f6r immunologi, genetik och patologi, Uppsala universitet<\/p>\n<p><em>Jeffrey Yachnin<\/em>, Docent, Kliniska Pr\u00f6vningsenheten, Onkologiska kliniken, Karolinska Universitetssjukhuset<\/p>\n<p>&nbsp;<\/p>\n<p>F\u00f6r mer information kontakta:<\/p>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)<\/p>\n<p>Telefon: 0709 &#8211; 42 83 03<\/p>\n<p>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\">david.westberg@nanexa.se<\/a><\/p>\n<p>www.nanexa.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Uppsala 2018-01-23\u00a0<\/p>\n<p>&nbsp;<\/p>\n<p>Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi<\/p>\n<p>Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/nanexa-forstarker-med-advisory-board-inom-onkologi\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1355","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Uppsala 2018-01-23\u00a0 &nbsp; Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-24T08:03:28+00:00\" \/>\n<meta name=\"author\" content=\"Anders Johansson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skriven av\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders Johansson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\"},\"author\":{\"name\":\"Anders Johansson\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/d26735c022a71d41737953c23a07692a\"},\"headline\":\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi\",\"datePublished\":\"2018-01-24T08:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\"},\"wordCount\":207,\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"articleSection\":[\"Nyheter\"],\"inLanguage\":\"sv-SE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\",\"name\":\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2018-01-24T08:03:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/d26735c022a71d41737953c23a07692a\",\"name\":\"Anders Johansson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"caption\":\"Anders Johansson\"},\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/author\\\/anders\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB","og_description":"Uppsala 2018-01-23\u00a0 &nbsp; Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","og_site_name":"Nanexa AB","article_published_time":"2018-01-24T08:03:28+00:00","author":"Anders Johansson","twitter_card":"summary_large_image","twitter_misc":{"Skriven av":"Anders Johansson","Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/#article","isPartOf":{"@id":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/"},"author":{"name":"Anders Johansson","@id":"https:\/\/nanexa.com\/#\/schema\/person\/d26735c022a71d41737953c23a07692a"},"headline":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi","datePublished":"2018-01-24T08:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/"},"wordCount":207,"publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"articleSection":["Nyheter"],"inLanguage":"sv-SE"},{"@type":"WebPage","@id":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","url":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","name":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2018-01-24T08:03:28+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/nanexa-forstarker-med-advisory-board-inom-onkologi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nanexa.com\/#\/schema\/person\/d26735c022a71d41737953c23a07692a","name":"Anders Johansson","image":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","caption":"Anders Johansson"},"url":"https:\/\/nanexa.com\/sv\/author\/anders\/"}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/comments?post=1355"}],"version-history":[{"count":1,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1355\/revisions"}],"predecessor-version":[{"id":1356,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1355\/revisions\/1356"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=1355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/categories?post=1355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/tags?post=1355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}